Needham analyst Matt McGinley initiated coverage of Aurora Cannabis with a Hold rating and $1.50 price target. The analyst notes that the investment by Canada's licensed cannabis producers has "far exceeded market development", with FY20 having to endure a period of infrastructure "rationalization". McGinley adds that Aurora is "deeply unprofitable", and like its peers will have to complete the task of drastic operating structure reduction while still growing its revenue. The analyst still expects the company to reach positive EBITDA by Q1 of FY21, though any shortfalls would likely place it into "liquidity risk".

In this edition of "Rising High," The Fly conducted an exclusive interview with Brendan Mitchel-Chesebro, industry analyst at BDSA, a Colorado-based cannabis market research and data analytics firm. Here are some... To see the rest of the story go to thefly.com. See Story Here

Latest data shows the largest indicative borrow rate increases among liquid option names include: Aurora Cannabis (ACB) 83.87% +1.16, B Riley Principal Merger Corp II (EOSE) 11.55% +1.08, ALTC Acquistion Corp (ALCC) 5.74% +1.02, VinFast Auto LTD (VFS) 124.46% +0.87, Sirius XM (SIRI) 13.95% +0.56, Medical Properties Trust (MPW) 10.91% +0.41, Spring Valley Acquisition Corp (SMR) 17.81% +0.38, Sellas Life Sciences (SLS) 69.10% +0.37, Valkyrie Bitcoin Miners ETF (WGMI) 2.31% +0.33, and Cassava Sciences (SAVA) 19.19% +0.33.